Wyeth Pharmaceuticals Awards $97,500 in Scholarships to the Hemophilia Community

Collegeville, Pa. (August 1, 2005) — Wyeth Pharmaceuticals has announced the winners of its annual hemophilia scholarship program - the Soozie Courter Sharing a Brighter Tomorrow Hemophilia Scholarship Program. Now in its eighth year, Wyeth recently increased the total funding for this program. This year, $97,500 in scholarships was awarded to students in the hemophilia community, including sixteen $5,000 undergraduate scholarships, two $7,500 graduate scholarships, and one $2,500 vocational scholarship.

The following individuals are scholarship recipients for the 2005-2006 academic year:

Undergraduate

• Patrick Lynch (Stewart Manor, NY) - Boston University
• Matthew Wofford (Chapel Hill, NC) - University of North Carolina, Chapel Hill
• Benjamin Murphy (Onancock, VA) - University of Virginia
• John Waldeisen (State College, PA) - Pennsylvania State University
• Michael Fitzpatrick (Concord, NH) - Keene State College
• Christopher Rasch* (Fairfield, OH) - Ohio Wesleyan University
• Brent Movitz (West Bloomfield, MI) - University of Michigan
• Daniel McDonald* (Wauwatosa, WI) - University of Wisconsin, Madison
• Timothy Harris (Spring, TX) - Texas State at San Marcos
• Kasey DeVine (Little Falls, MN) - St. John's University
• Casey Baugh (Providence, UT) - Utah Valley State College
• Stephen Uhrbach (Pincher Creek, Alberta) - University of Alberta
• Byron Jasper (Houma, LA) - Xavier University of Louisiana
• Gregory Price (Falls Church, VA) - Carnegie Mellon University
• Paul Wilton (London, ON) - King's University College
• Vishnu Calvin Lakhan (Brampton, ON) - York University

Graduate

• Craig Wright* (Franklin, TN) - Lipscomb University
• Jeffrey Barlekamp* (Clifton, NJ) - University of California, Berkeley, School of Law

Vocational

• Jason Simmonds* (Annandale, MN) - St. Cloud Technical College

"We are very pleased to continue our tradition of supporting education in the hemophilia community and recognizing academic achievement," said Dr. Gary L. Stiles, Executive Vice President and Chief Medical Officer of Wyeth Pharmaceuticals.

*Indicates a repeat scholarship winner.

To be eligible for the scholarships, students must have either hemophilia A or hemophilia B, and be either a high school senior or have a graduate equivalency diploma (GED) or currently be enrolled in an accredited junior college, college (undergraduate or graduate), or vocational school.

The scholarship applicants are required to provide a personal essay or statement, information on their academic achievements, and letters of recommendation. A committee of hemophilia health care providers reviews the applications and selects scholarship winners. More than 130 individuals from 39 states, Puerto Rico, and Canada applied to the scholarship program this year.

Applications for the Soozie Courter Sharing a Brighter Tomorrow Hemophilia Scholarship Program 2006-2007 academic year will be available in the fall. To receive an application, please call the Wyeth Hemophilia Hotline at 888-999-2349 or visit www.hemophiliavillage.com.

The scholarships are dedicated to the memory of Soozie Courter, RN, and her contributions to the hemophilia community. During her career in the pharmaceutical industry, Courter worked on developing products to treat hemophilia. By naming the scholarships in her honor, Wyeth recognizes Courter's passion and interest in all issues related to the scientific advancement of hemophilia research.

Hemophilia is a rare, inherited blood clotting disorder for which there currently is no cure. People with hemophilia are deficient in one of the key proteins — either factor VIII (hemophilia A) or factor IX (hemophilia B) — that are vital in the clotting cascade to prevent bleeding. Both forms of hemophilia are characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. In the United States, approximately 17,000 people have hemophilia.

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise

Back to News